A clinical and scientific overview of tositumomab and iodine I 131 tositumomab

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

Peter McLaughlin, A.J. Grillo-López, Brian K. Link et al. · Journal of Clinical Oncology · 1998 · 2.8K citations

Pharmacy, Hematology, Immunology +17

New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project.

J. O. Armitage, Dennis D. Weisenburger · Journal of Clinical Oncology · 1998 · 1.3K citations

Veterinary Medicine, Hematology, Pathology +14

Treatment of Patients With Low-Grade B-Cell Lymphoma With the Combination of Chimeric Anti-CD20 Monoclonal Antibody and CHOP Chemotherapy

M. S. Czuczman, A.J. Grillo-López, Christine A. White et al. · Journal of Clinical Oncology · 1999 · 856 citations

Medicine, Hematology, Oncology +15

Pivotal Study of Iodine I 131 Tositumomab for Chemotherapy-Refractory Low-Grade or Transformed Low-Grade B-Cell Non-Hodgkin’s Lymphomas

Mark Kaminski, Andrew D. Zelenetz, Oliver W. Press et al. · Journal of Clinical Oncology · 2001 · 586 citations

Medicine, Oncology, Pharmacology +15

Apoptosis of Malignant Human B Cells by Ligation of CD20 With Monoclonal Antibodies

Daming Shan, Jeffrey A. Ledbetter, Oliver W. Press · Blood · 1998 · 571 citations · Full text

Life Sciences, Immunology, Molecular Biology +14